Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020115288 - MARQUEURS BIOLOGIQUES POUR ÉVÉNEMENTS CARDIOVASCULAIRES


Avertissement La version image (PDF) disponible dans PATENTSCOPE est la version officielle. Cette version HTML en ligne est fournie pour aider les utilisateurs. Malgré le grand soin apporté à la compilation pour assurer une représentation précise et exacte des données figurant sur le document/les images imprimés, des erreurs et/ou des omissions ne peuvent pas être exclues en raison des processus de transmission et de conversion de données et des limitations inhérentes aux processus de traduction (éventuellement) automatique utilisés. Les liens hypertexte suivis de ce symbole sont associés à des ressources externes qui ne sont pas contrôlées par l'OMPI. L'OMPI décline toute responsabilité concernant les points mentionnés ci-dessus.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/EP2019/084008 ZOR22641PCT
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
06 December 2019 06 December 2018
Applicant
ZORA BIOSCIENCES OY
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
This International Searching Authority found multiple inventions in this international application, as follows:
1. claims: 178(completely); 1-4, 6-25, 27-31, 33-177, 179, 181, 183, 185-237(partially)
Biomarker composition comprising Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1, 24:1), Cer(d18:1/ 24:0), PC 16:0/22:5, PC 14:0/22:6 and PC 16:0/16:0 and related embodiments.
2. claims: 180(completely); 1-4, 6-25, 27-31, 33-177, 179, 181, 183, 185-237(partially)
Biomarker composition comprising Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1, 24:1), Cer(d18:1/ 24:0), PC 16:0/22:5, PC 16:0/22:6 and PC 16:0/16:0 and related embodiments.
3. claims: 182(completely); 1-4, 6-25, 27-31, 33-177, 179, 181, 183, 185-237(partially)
Biomarker composition comprising Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1, 24:1), Cer(d18:1/ 24:0), PC 16:0/22:5, PC 16:0/22:6 and PC 16:0/18:3 and related embodiments.
4. claims: 184(completely); 1-4, 6-25, 27-31, 33-177, 179, 181, 183, 185-237(partially)
Biomarker composition comprising Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1, 24:1), PC 16:0/20:4, PC 18:0/20:4 and PC 38:7 and related embodiments.
5-20. claims: 1-4, 6-25, 27-31, 33-177, 179, 181, 183, 185-237(all partially)
Biomarker composition comprising any of the Cer listed in claim 169 and 175, excluding Cer(d18:1/16:0), and related embodiments.
6. claims: 5, 26, 32
Method of treating CVD.
1.
As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.
As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3.
As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.
No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 178(completely); 1-4, 6-25, 27-31, 33-177, 179, 181, 183, 185-237(partially)
Remark on Protest
The additional search fees were accompanied by the applicant’s protest and, where applicable, the payment of a protest fee.
The additional search fees were accompanied by the applicant’s protest but the applicable protest fee was not paid within the time limit specified in the invitation.
No protest accompanied the payment of additional search fees.
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No. ____________
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     G01N 33/92 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     G01N
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
WO 2011138419 A1 (ZORA BIOSCIENCES OY [FI]; LAAKSONEN REIJO [FI] ET AL.) 10 November 2011 (2011-11-10)
6-20,33-44,51-57,78-83,90-94,98-103
cited in the application
A
Abstract; examples; claims
1-4,21-25,27-31,45-50,58-77,84-89,95-97,104-179,181,183,185-237
(2)
X
PIYUSHKUMAR A. MUNDRA ET AL, "Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention", JCI INSIGHT,Vol. 3, No. 17, 06 September 2018 (2018-09-06),
XP055658414
6-20,33-44,51-57,78-83,90-94,98-103
A
Abstract; Fig. 2; Table 4.
1-4,21-25,27-31,45-50,58-77,84-89,95-97,104-179,181,183,185-237
(3)
X
KAUHANEN DIMPLE ET AL, "Development and validation of a high-throughput LC-MS/MS assay for routine measurement of molecular ceramides", 27 February 2016 (2016-02-27), Vol. 408, No. 13, page 3475-3483,
XP035867729
[retrieved on  2016-02-27]
6-20,33-44,51-57,78-83,90-94,98-103
A
Abstract
1-4,21-25,27-31,45-50,58-77,84-89,95-97,104-179,181,183,185-237
(4)
X,P
MIKA HILVO ET AL, "Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients", EUROPEAN HEART JOURNAL,18 June 2019 (2019-06-18),
XP055658304
1-4,6-25,27-31,33-179,181,183,185-237
the whole document
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"D"
document cited by the applicant in the international application
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
WO 2011138419 A1
10 November 2011
CA 2798238 A1
CN 102971633 A
DK 2385374 T3
DK 2567240 T3
EP 2385374 A1
EP 2567240 A1
EP 3399318 A1
ES 2455124 T3
ES 2672054 T3
JP 5871244 B2
JP 2013527449 A
NO 2385374 T3
NO 2567240 T3
US 2013045217 A1
US 2015247873 A1
US 2016363601 A1
US 2018321266 A1
WO 2011138419 A1
10 November 2011
13 March 2013
17 March 2014
14 June 2018
09 November 2011
13 March 2013
07 November 2018
14 April 2014
12 June 2018
01 March 2016
27 June 2013
07 June 2014
01 September 2018
21 February 2013
03 September 2015
15 December 2016
08 November 2018
10 November 2011
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
23 January 2020
Date of mailing of the international search report:
31 March 2020
Authorized officer:
López García, F
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E